Navigation Links
InSet Technologies Appoints Jon Tremmel to its Board of Directors
Date:5/9/2008

MT. OLIVE, N.J., May 9 /PRNewswire/ -- InSet Technologies, an emerging leader in the development of implantable drug infusion pumps for targeted delivery of medications, announced today the addition of Jon Tremmel to its Board of Directors.

Before retiring from Medtronic Inc. after nearly 30 years of service, Jon held a number of senior leadership positions including President of the Neurological Division, President of the Physio-Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division.

"InSet Technologies has a very innovative product in clinical trials right now, and I look forward to being part of this growing company," said Jon Tremmel. "I have spent most of my career seeking technological solutions to help patients manage chronic conditions. None is more important to me than finding more effective methods to manage the debilitating conditions of chronic pain."

Mr. Tremmel also has served as a key member of the Medtronic Senior Management Operating Committee. He achieved a Masters Degree in Engineering from Boston University and a MBA from the University of Minnesota. Jon presently resides in Minneapolis, Minnesota, with his family and is an active member of the Minnesota Zoo Board, in addition to various Board positions for other companies.

"InSet has made substantial progress in the development of a new generation of implantable drug infusion pump technologies. Jon brings a wealth of business expertise that will contribute to our growth and enhance value to our shareholders," said Steve Adler, President and CEO of Inset Technologies. "We look forward to his contribution to our company at this important time in our history."

About InSet

InSet Technologies Incorporated (http://www.insetinc.com) headquartered in Mt. Olive, NJ is a development-stage medical device company. Its first product, the Prometra(R) programmable, implantable drug infusion pump is undergoing clinical trials for the treatment of chronic pain. About 70 million people in the United States live with chronic pain. Chronic pain costs the U.S. more in lost productivity and treatment than heart disease and cancer combined.

CAUTION: Prometra(R) pumps are Investigational Devices, which have not yet been approved by the FDA.


'/>"/>
SOURCE InSet Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):